We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 23

NanoString seeks $55 million to advance breast cancer test

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • January 30 2014

NanoString Technologies, Inc., which develops life-science research tools, including analytical systems used by cancer researchers to study the

Biotech raises $57.4 million in IPO

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • January 30 2014

GlycoMimetics, Inc., a biotechology company focusing on the development of treatments for blood cancers and inflammatory diseases, has closed its

Biotech Genocea Biosciences files IPO to fund vaccine development

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • January 9 2014

Genocea Biosciences, Inc. has filed a registration statement with the U.S. Securities and Exchange Commission relating to a proposed initial public

Cancer biotech seeks $69 million in IPO

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • January 9 2014

Dicerna Pharmaceuticals, Inc. has filed a registration statement with the U.S. Securities and Exchange Commission indicating its intent to raise up

Can biotech investor confidence continue?

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • December 12 2013

Nature Biotechnology Business Editor Brady Huggett recently examined the 2013 surge in biotechnology initial public offerings (IPOs) and considers

Ultragenyx files with SEC to raise $86.25 million in IPO

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • November 21 2013

Orphan disease drug developer Ultragenyx Pharmaceutical Inc. has filed a registration statement with the U.S. Securities and Exchange Commission

Boston region surges ahead in biotech IPOs

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • November 21 2013

According to an analysis of initial public offering (IPO) data from 2013, xconomy's National Biotech Editor Luke Timmerman has concluded that Boston

Biopharmaceutical sets $150-million IPO terms

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • November 21 2013

According to a news source, Redwood City, California-based Relypsa, Inc. seeks to raise $150 million by offering more than 7.87 million shares priced

Aerie Pharmaceuticals seeks to raise $58 million in IPO to advance glaucoma drug

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • September 26 2013

Aerie Pharmaceuticals, Inc., has filed a Form S-1 registration statement with the U.S. Securities and Exchange Commission outlining its plans to

Cancer diagnostics company increases IPO goal

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • September 26 2013

Since announcing the terms for its initial public offering (IPO) earlier in September, Foundation Medicine, Inc. has reportedly boosted its goal from